|
시장보고서
상품코드
2064676
RNAi 기술 시장 규모, 점유율 및 성장 분석 : 분자 유형별, 전달 기술별, 응용 분야별, 최종 이용 산업별, 지역별 - 업계 예측(2026-2033년)RNAI Technology Market Size, Share, and Growth Analysis, By Molecule Type (siRNA, miRNA), By Delivery Technology (Lipid Nanoparticles, Polymer & Conjugate Systems), By Application Area, By End-Use Industry, By Region - Industry Forecast 2026-2033 |
||||||
세계의 RNAi 기술 시장 규모는 2024년에 35억 8,000만 달러로 평가되었고, 2025년 41억 2,000만 달러에서 2033년까지 127억 9,000만 달러로 확대되어 예측 기간(2026-2033년)에 CAGR 15.2%를 기록할 것으로 예측됩니다.
RNAi 기술 시장은 치료제, 연구용 시약, 농업 분야에서의 서열 특이적 유전자 침묵화에 초점을 맞추고 있으며, 그 주요 촉진요인은 치료가 어려운 질환의 경로에 영향을 미칠 수 있는 능력에 있습니다. 지질 나노입자 및 GalNAc 접합체를 포함한 첨단 전달 기술은 중요한 성장 촉진요인으로, 표적에 대한 도달 정확도를 높이고 전신 노출을 최소화함으로써 안전성 우려를 해소하며 임상 검증을 가능하게 하고 있습니다. 의약품 승인은 투자자들의 신뢰를 높여주며, 그 결과 순환기학 및 종양학 등 다양한 분야에서 제휴 및 포트폴리오 확대로 이어지고 있습니다. 또한, 인공지능(AI)은 표적 식별을 효율화하고, siRNA 서열 설계를 최적화하며, 후보 화합물의 우선순위 지정을 강화함으로써 RNAi 신약 개발에 혁명을 일으키고 있습니다. RNAi 개발 기업과 AI 기업 간의 협력은 이 역동적인 분야의 상용화를 가속화하고 수익 기회를 극대화할 것으로 예측됩니다.
세계 RNAi 기술 시장은 분자 유형, 전달 기술, 응용 분야, 최종 이용 산업 및 지역별로 분류됩니다. 분자 유형에 따라 시장은 siRNA, miRNA, shRNA 및 기타로 분류됩니다. 전달 기술을 기준으로 볼 때, 시장은 지질 나노입자, 고분자 및 접합체 시스템, 바이러스 벡터, 그리고 신흥 나노소재로 분류됩니다. 응용 분야에 따라 시장은 치료제, 신약 개발 및 스크리닝, 진단, 농업으로 분류됩니다. 최종 이용 산업에 따라 시장은 제약·생명공학 기업, 위탁 개발·제조 기관(CDMO), 학술·연구 기관, 진단실험실로 분류됩니다. 지역별로 볼 때, 시장은 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 분류됩니다.
세계 RNAi 기술 시장의 성장 요인
세계 RNAi 기술 시장은 나노입자 운반체, 지질 제제 및 결합 화학 분야의 혁신에 힘입어 크게 성장하고 있으며, 이러한 혁신은 RNAi 치료제가 효과적으로 표적화할 수 있는 조직의 범위를 확대되고 있습니다. 이러한 발전 덕분에 전달상의 장벽이 최소화되어 임상적 실현 가능성이 높아지고 있습니다. 전달 플랫폼의 강화는 기술적 장벽을 낮추고, 보다 예측 가능한 약동학 및 생체 내 분포를 제공함으로써 개발자와 투자자의 신뢰를 높이고 있습니다. 이를 통해 연구 프로젝트에서 개념 단계에서 전임상 검증 단계로의 전환이 원활해지고, 수탁 개발 업체와의 제휴가 더욱 매력적으로 변하며, 전체 파이프라인이 다양화됩니다. 이 모든 것이 시장의 지속적인 성장에 기여하고 있습니다.
세계 RNAi 기술 시장의 제약 요인
세계 RNAi 기술 시장은 신규 RNAi 제품 평가에 따른 불확실성과 지역별로 상이한 규제 요건으로 인해 심각한 제약에 직면해 있습니다. 이러한 격차는 개발 기간의 장기화를 초래하여, 후원사에게 인지적 및 관리적 측면에서 더 큰 부담을 안길 가능성이 있습니다. 장기적인 안전성을 입증하기 위한 복잡한 기준은 물론, 혁신적인 제조 관리 및 생체 분포 연구에 대한 요구로 인해 종합적인 전임상 및 임상 데이터가 필요합니다. 이는 소규모 개발자들이 주저하게 만들고, 포트폴리오 확장을 저해할 가능성이 있습니다. 게다가, 다양한 규제 체계에 대응하는 것은 비용을 증가시키고, 전 세계의 개발 전략을 복잡하게 만듭니다. 그 결과, 신중한 투자 태도, 시장 진입 지연, 프로그램 우선순위 결정에 있어 보수적인 태도가 나타나게 되며, 결국 시장 전체의 발전을 저해하게 됩니다.
세계 RNAi 기술 시장 동향
세계 RNAi 기술 시장에서는 나노입자 공학 및 결합 화학의 혁신에 힘입어, 첨단 전달 기술로의 뚜렷한 추세가 나타나고 있습니다. 이러한 진화를 통해 RNAi 치료제의 약동학을 개선하고, 환자의 치료 순응도와 조직 특이성을 높이는 비침습적이며 표적 지향적인 운반체의 개발이 가능해졌습니다. 각 기업은 임상 적용에 따른 과제를 해결하기 위해 전달 기술 전문가들과 전략적으로 제휴하고 있으며, 그 결과 다양한 요구에 부응하는 제제가 개발되고 있습니다. 실제 임상에서의 적용 사례와 모듈식 전달 툴킷이 축적됨에 따라, 업계에서는 개발 기간 단축이 기대되고 있으며, 이를 통해 RNAi의 적용 범위가 수많은 질환 분야로 확대되어 치료 분야에서 혁신적인 존재로서의 입지가 확고해질 것으로 전망됩니다.
자주 묻는 질문
목차
서론
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 RNAi 기술 시장 규모 : 분자 유형별
세계의 RNAi 기술 시장 규모 : 배송 기술별
세계의 RNAi 기술 시장 규모 : 용도별
세계의 RNAi 기술 시장 규모 : 최종 사용 산업별
세계의 RNAi 기술 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
LSH 26.06.29Global Rnai Technology Market size was valued at USD 3.58 Billion in 2024 and is poised to grow from USD 4.12 Billion in 2025 to USD 12.79 Billion by 2033, growing at a CAGR of 15.2% during the forecast period (2026-2033).
The RNAi technology market focuses on sequence-specific gene silencing across therapeutics, research reagents, and agricultural applications, with its primary catalyst being the capacity to influence challenging disease pathways. Enhanced delivery technologies, including lipid nanoparticles and GalNAc conjugates, are crucial growth enhancers, facilitating improved targeting and minimizing systemic exposure, which have addressed safety concerns and enabled clinical validation. Successful drug approvals have spurred increased investor confidence, leading to partnerships and expanded portfolios in diverse fields such as cardiology and oncology. Additionally, artificial intelligence is revolutionizing RNAi drug discovery by streamlining target identification, optimizing siRNA sequence design, and enhancing candidate prioritization. The collaboration between RNAi developers and AI firms is poised to accelerate commercialization and maximize revenue opportunities in this dynamic sector.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Rnai Technology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Rnai Technology Market Segments Analysis
The global RNAi technology market is segmented by molecule type, delivery technology, application area, end-use industry and region. Based on molecule type, the market is segmented into siRNA, miRNA, shRNA and Others. Based on delivery technology, the market is segmented into Lipid Nanoparticles, Polymer & Conjugate Systems, Viral Vectors and Emerging Nanomaterials. Based on application area, the market is segmented into Therapeutics, Drug Discovery & Screening, Diagnostics and Agriculture. Based on end-use industry, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Development & Manufacturing Organizations, Academic & Research Institutes and Diagnostic Laboratories. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Rnai Technology Market
The global RNAi technology market is significantly driven by innovations in nanoparticle carriers, lipid formulations, and conjugation chemistries, which have expanded the range of tissues that RNAi therapeutics can effectively target. These advancements minimize delivery obstacles and enhance clinical viability. Enhanced delivery platforms instill greater confidence among developers and investors by lowering technical barriers and providing more predictable pharmacokinetics and biodistribution. This encourages a smoother transition from conceptual ideas to preclinical validation in research initiatives, making collaborations with contract developers more appealing and diversifying the overall pipeline, all contributing to sustained growth in the market.
Restraints in the Global Rnai Technology Market
The global RNAi technology market faces significant constraints stemming from uncertainties in evaluating novel RNAi products and the varying regulatory requirements across different regions. These disparities can result in prolonged development timelines and place a heavier cognitive and administrative burden on sponsors. The intricate criteria for proving long-term safety, alongside demands for innovative manufacturing controls and biodistribution studies, necessitate comprehensive preclinical and clinical data, which may deter smaller developers and hinder portfolio growth. Additionally, navigating diverse regulatory frameworks increases costs and complicates global development strategies, resulting in cautious investment approaches, delayed market entry, and a conservative focus on program prioritization that ultimately hampers overall market progress.
Market Trends of the Global Rnai Technology Market
The global RNAi technology market is witnessing a notable trend towards advanced delivery modalities, driven by innovations in nanoparticle engineering and conjugation chemistries. This evolution enables the development of noninvasive and targeted carriers that enhance the pharmacokinetics of RNAi therapeutics, improving patient compliance and tissue specificity. Companies are strategically collaborating with delivery specialists to address clinical translation challenges, resulting in a diverse range of tailored formulations. As real-world applications and modular delivery toolkits accumulate, the industry anticipates accelerated development timelines, expanding the reach of RNAi across numerous disease areas and solidifying its position as a transformative force in therapeutics.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global RNAI Technology Market Size by Molecule Type & CAGR (2026-2033)
- Market Overview
- siRNA
- miRNA
- shRNA
- Others
Global RNAI Technology Market Size by Delivery Technology & CAGR (2026-2033)
- Market Overview
- Lipid Nanoparticles
- Ionizable LNPs
- Liposomes
- Polymer & Conjugate Systems
- GalNAc Conjugates
- PEGylated Carriers
- Viral Vectors
- Adeno-Associated Virus
- Lentiviral Vectors
- Emerging Nanomaterials
Global RNAI Technology Market Size by Application Area & CAGR (2026-2033)
- Market Overview
- Therapeutics
- Oncology
- Cardiometabolic Disorders
- Infectious Diseases
- Neurological & Rare Genetic Disorders
- Drug Discovery & Screening
- Diagnostics
- Agriculture
Global RNAI Technology Market Size by End-Use Industry & CAGR (2026-2033)
- Market Overview
- Pharmaceutical & Biotechnology Companies
- Contract Development & Manufacturing Organizations
- Academic & Research Institutes
- Diagnostic Laboratories
Global RNAI Technology Market Size & CAGR (2026-2033)
- North America (Molecule Type, Delivery Technology, Application Area, End-Use Industry)
- US
- Canada
- Europe (Molecule Type, Delivery Technology, Application Area, End-Use Industry)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Molecule Type, Delivery Technology, Application Area, End-Use Industry)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Molecule Type, Delivery Technology, Application Area, End-Use Industry)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Molecule Type, Delivery Technology, Application Area, End-Use Industry)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Alnylam Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Arrowhead Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ionis Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dicerna Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Silence Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Quark Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gradalis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sylentis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sirnaomics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck KGaA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Qiagen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Danaher Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Agilent Technologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio-Rad Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GenScript Biotech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takara Bio
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Promega Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Horizon Discovery
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- System Biosciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
